加拿大胃肠病学会炎症性肠病患者免疫接种临床实践指南(第2部分:灭活疫苗)
该指南由加拿大胃肠病学会制定、美国胃肠病学会认可,针对成人及儿童炎症性肠病(IBD)患者的灭活疫苗接种提出推荐。基于系统评价和GRADE方法,20个问题中15个达成共识,多数推荐与CDC及加拿大NACI一致,但某些疫苗建议扩展至更宽年龄或低风险人群;5个问题因证据不足未达成共识。
要点
- IBD本身不是灭活疫苗接种的禁忌证,但免疫抑制治疗可能降低疫苗反应。
- 多数灭活疫苗推荐与普通人群一致,但 Hib 疫苗建议>5岁、重组带状疱疹疫苗建议<50岁成人、乙肝疫苗建议无风险成人。
- 双倍剂量乙肝疫苗、生物制剂流感时机、无风险成人肺炎球菌/脑膜炎球菌疫苗及27-45岁HPV疫苗未达成共识。
核心结论
- IBD患者可能面临某些疫苗可预防疾病风险增加,维持适当接种状态对优化结局至关重要。
- 总体上IBD不是灭活疫苗的禁忌证,但免疫抑制治疗可能降低疫苗应答。
研究设计与样本
- 加拿大胃肠病学会制定、美国胃肠病学会认可的临床实践指南,聚焦灭活疫苗。
- 通过系统评价评估IBD患者、其他免疫介导炎性疾病患者及普通人群的疫苗效力、效果和安全性。
- 采用GRADE方法评级证据确定性和推荐强度,通过在线平台迭代开发关键问题并由多学科组投票。
- 使用Evidence-to-Decision框架制定推荐,强推荐意味着多数患者应接受推荐措施,条件推荐意味着不同患者适合不同选择。
主要发现
- 20个问题中15个达成共识,推荐涉及流感嗜血杆菌b型、重组带状疱疹、乙型肝炎、流感、肺炎球菌、脑膜炎球菌、破伤风-白喉-百日咳和人类乳头瘤病毒疫苗。
- 多数IBD患者推荐与CDC及加拿大NACI普通人群推荐一致,但以下例外:>5岁患者建议Hib疫苗、<50岁成人建议重组带状疱疹疫苗、无风险因素成人建议乙肝疫苗。
- 5个陈述未达成共识且未做推荐,主要因证据缺乏,包括双倍剂量乙肝疫苗、生物制剂患者流感免疫时机、无风险因素成人肺炎球菌和脑膜炎球菌疫苗、27-45岁人群HPV疫苗。
关键数值与推荐
- 强推荐表示多数患者应接受推荐措施;条件推荐表示不同患者适合不同选择。
- 推荐涉及疫苗:Hib、重组带状疱疹、乙肝、流感、肺炎球菌、脑膜炎球菌、Tdap、HPV。
- 例外推荐:>5岁IBD患者建议Hib疫苗;<50岁成人建议重组带状疱疹疫苗;无风险因素成人建议乙肝疫苗。
- 未达成共识的5个陈述:双倍剂量乙肝疫苗、生物制剂患者流感免疫时机、无风险因素成人肺炎球菌疫苗、无风险因素成人脑膜炎球菌疫苗、27-45岁人群HPV疫苗。
临床怎么用
- IBD患者应维持适当的灭活疫苗接种状态以优化结局。
- 免疫抑制治疗可能降低疫苗应答,接种时需考虑此因素。
- 多数灭活疫苗按普通人群推荐接种,但Hib、重组带状疱疹和乙肝疫苗在某些年龄或风险人群中有扩展推荐。
- 对于未达成共识的疫苗问题,需结合个体情况谨慎决策。
局限性
- 5个陈述因证据缺乏未达成共识,未做推荐。
- 免疫原性被作为疫苗效力的替代结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The effectiveness and safety of vaccinations can be altered by immunosuppressive therapies, and perhaps by inflammatory bowel disease (IBD) itself. These recommendations developed by the Canadian Association of Gastroenterology and endorsed by the American Gastroenterological Association, aim to provide guidance on immunizations in adult and pediatric patients with IBD. This publication focused on inactivated vaccines. METHODS: Systematic reviews evaluating the efficacy, effectiveness, and safety of vaccines in patients with IBD, other immune-mediated inflammatory diseases, and the general population were performed. Critical outcomes included mortality, vaccine-preventable diseases, and serious adverse events. Immunogenicity was considered a surrogate outcome for vaccine efficacy. Certainty of evidence and strength of recommendations were rated according to the GRADE (Grading of Recommendation Assessment, Development, and Evaluation) approach. Key questions were developed through an iterative online platform, and voted on by a multidisciplinary group. Recommendations were formulated using the Evidence-to-Decision framework. Strong recommendation means that most patients should receive the recommended course of action, whereas a conditional recommendation means that different choices will be appropriate for different patients. RESULTS: Consensus was reached on 15 of 20 questions. Recommendations address the following vaccines: Haemophilus influenzae type b, recombinant zoster, hepatitis B, influenza, pneumococcus, meningococcus, tetanus-diphtheria-pertussis, and human papillomavirus. Most of the recommendations for patients with IBD are congruent with the current Centers for Disease Control and Prevention and Canada's National Advisory Committee on Immunization recommendations for the general population, with the following exceptions. In patients with IBD, the panel suggested Haemophilus influenzae type b vaccine for patients older than 5 years of age, recombinant zoster vaccine for adults younger than 50 year of age, and hepatitis B vaccine for adults without a risk factor. Consensus was not reached, and recommendations were not made for 5 statements, due largely to lack of evidence, including double-dose hepatitis B vaccine, timing of influenza immunization in patients on biologics, pneumococcal and meningococcal vaccines in adult patients without risk factors, and human papillomavirus vaccine in patients aged 27-45 years. CONCLUSIONS: Patients with IBD may be at increased risk of some vaccine-preventable diseases. Therefore, maintaining appropriate vaccination status in these patients is critical to optimize patient outcomes. In general, IBD is not a contraindication to the use of inactivated vaccines, but immunosuppressive therapy may reduce vaccine responses.
引用
- Jones JL, Tse F, Carroll MW, et al. Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)-Part 2: Inactivated Vaccines. Gastroenterology. 2021. PMID: 34334167. doi:10.1053/j.gastro.2021.04.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。